256 related articles for article (PubMed ID: 32702178)
1. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
3. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
4. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
5. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of gastric neuroendocrine tumours.
Plöckinger U
Wien Klin Wochenschr; 2007; 119(19-20):570-2. PubMed ID: 17985089
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis.
Dilaghi E; Bellisario M; Esposito G; Carabotti M; Annibale B; Lahner E
Front Immunol; 2022; 13():910077. PubMed ID: 35935934
[TBL] [Abstract][Full Text] [Related]
8. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
[TBL] [Abstract][Full Text] [Related]
9. Factors related to gastric neuroendocrine tumors.
Soto-Solís R; Romano-Munive AF; Santana de Anda K; Barreto-Zuñiga R
Rev Gastroenterol Mex (Engl Ed); 2019; 84(1):52-56. PubMed ID: 29705524
[TBL] [Abstract][Full Text] [Related]
10. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
12. Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach.
Takahari K; Haruma K; Ohtani H; Kiyoto S; Watanabe A; Kamada T; Manabe N; Hatano Y
Intern Med; 2017 Oct; 56(20):2699-2703. PubMed ID: 28924108
[TBL] [Abstract][Full Text] [Related]
13. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
14. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
15. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study.
Kiso M; Ito M; Boda T; Kotachi T; Masuda K; Hata K; Sasaki A; Kawamura T; Yoshihara M; Tanaka S; Chayama K
Scand J Gastroenterol; 2017 Aug; 52(8):828-832. PubMed ID: 28485638
[TBL] [Abstract][Full Text] [Related]
17. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.
Campana D; Ravizza D; Ferolla P; Faggiano A; Grimaldi F; Albertelli M; Ricci C; Santini D; Brighi N; Fazio N; Colao A; Ferone D; Tomassetti P
Endocrine; 2017 Jun; 56(3):633-638. PubMed ID: 27592118
[TBL] [Abstract][Full Text] [Related]
19. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
[TBL] [Abstract][Full Text] [Related]
20. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
